Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience

Theresia Akhlaghi, Jose Fernandez-Rengifo, Mateo Mejia Saldarriaga, Sarah C. Rutherford, Cara Rosenbaum, Jorge Monge, Peter Martin, John N. Allan, Richard R. Furman, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 6350.

https://doi.org/10.1182/blood-2024-210059

Published: 2024

Journal Articles

Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab

Cara Rosenbaum, Michaela Liedtke, Paul Christos, Hyemin Kim, Kathleen Pogonowski, Natalie Agudo, Bruna Barroso, Anthony Shelton, Samantha Reilly, Courtney Gadbois, John Mark Sloan, Vaishali Sanchorawala, Anita D'Souza

Blood (2023) 142 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2023-191133

Published: 2023

Journal Articles

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Mateo Mejia Saldarriaga, Caitlin Unkenholz, Joshua A Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, Markus Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2023) 142 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2023-187832

Published: 2023

Journal Articles

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Blood (2020) 136 (26): 3033–3040.

https://doi.org/10.1182/blood.2020008150

Published: 2020

Includes: Supplemental data

Journal Articles

Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.

Shaji K. Kumar, MD, Amrita Krishnan, MD, Vivek Roy, M.D., Todd M Zimmerman, MD, Morie Abraham A Gertz, MD, Keith E. Stockerl-Goldstein, MD, Francis K Buadi, M.D., Cara Rosenbaum, MD, Ann Birgin, CRA, Mark Fiala, BS, CCRP, Valeria Jiminez, Michele Maharaj, RN, Michael N. Needle, MD, Ravi Vij, MD

Blood (2012) 120 (21): 2965.

https://doi.org/10.1182/blood.V120.21.2965.2965

Published: 2012

Journal Articles

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Philip L. McCarthy, MD, Kouros Owzar, PhD, Kenneth C. Anderson, Craig C. Hofmeister, MD, David Duane Hurd, MD, Hani Hassoun, MD, Sergio Giralt, MD, Edward A. Stadtmauer, MD, Paul G Richardson, MD, Daniel J. Weisdorf, MD, Ravi Vij, MBBS, MD, Jan S Moreb, MD, Natalie Scott Callander, MD, Koen Van Besien, MD, Teresa Gentile, MD, PhD, Luis Isola, MD, Richard T Maziarz, MD, Don A. Gabriel, MD, PhD, Asad Bashey, MD, PhD, Heather Landau, MD, Thomas Martin, MD, Muzaffar H. Qazilbash, MD, Denise Levitan, MD, Brian McClune, MD, Vera Hars, MS, John Postiglione, BA, Chen Jiang, PhD, Elizabeth Bennett, BS, Susan S Barry, BA, Linda Bressler, PharmD, Michael Kelly, MA, Michele Sexton, MS, Cara Rosenbaum, MD, Hari Parameswaran, MD, MS, Marcelo C Pasquini, MD, MS, Mary M. Horowitz, MD, MS, Thomas C. Shea, MD, Steven M Devine, MD, Charles Linker, MD

Blood (2010) 116 (21): 37.

https://doi.org/10.1182/blood.V116.21.37.37

Published: 2010

NARROW

Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience

Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Email alerts

ASH Publications

American Society of Hematology

Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience

Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only